Arrhythmia

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, March 11, 2024

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Thursday, March 7, 2024

MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced results from two new clinical data analyses from the AVOID-HF trial, which demonstrate the benefits of its Aquadex System in reducing heart failure readmissions at 30 days. Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.

Key Points: 
  • Results from the analyses were presented in a late-breaking session at the Technology and Heart Failure Therapeutics (THT) conference in Boston.
  • Key findings demonstrating the benefits of AUF include:
    Fewer heart failure events and heart failure hospitalizations: AUF patients had significantly fewer heart failure events within 30 days compared to ALD (90% vs 77.3% p=0.0138) and fewer heart failure hospitalizations for the AUF patients compared to the ALD patients (90.0% vs. 79.2% p=0.0321) within 30 days.
  • Key findings from the analysis include:
    Top predictors for 90-day heart failure events: Using ML, the study identified the top 10 predictors for 90-day heart failure events.
  • Strong results for super-responders: 90% of patients categorized as super-responders to AUF therapy within this model did not experience any 90-day heart failure events.

REMSleep Holdings Shareholder Update

Retrieved on: 
Monday, March 4, 2024

CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.

Key Points: 
  • CLEARWATER, FL, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - REMSleep Holdings, Inc. (OTC PINK: RMSL) gives an update on FDA process and REMSleep status.
  • We have had numerous inquiries asking for REMSleep regulatory status update.
  • REMSleep consultants are confident we will receive our 510(K) and we will never give up until we are successful.
  • REMSleep has addressed this problem by developing a novel CPAP nasal pillow interface that has been engineered to reduce pressure and enable better airflow.

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Retrieved on: 
Monday, March 4, 2024

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress.

Key Points: 
  • Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress.
  • Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% vs. 13.2%, respectively).
  • CardiAMP cell therapy was also associated with trends toward reduced ventricular tachyarrhythmias, enhanced heart function as measured by left ventricular ejection fraction, and improved NTproBNP.
  • “These positive results for CardiAMP cell therapy are very encouraging, especially for patients with elevated NTproBNP, who encompass the majority of heart failure patients that we see in our daily practice,” said trial co-principal investigator Dr. Raval.

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, March 4, 2024

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

Retrieved on: 
Thursday, February 29, 2024

“Our work with Epic aligns with our goal to optimize clinician workflow efficiencies and provide seamless access to our Zio services.

Key Points: 
  • “Our work with Epic aligns with our goal to optimize clinician workflow efficiencies and provide seamless access to our Zio services.
  • “We believe this integration facilitates improved patient care, ensuring that our customers and their staff can focus on what truly matters—patient health.
  • iRhythm has already surpassed 1.5 million all-time registrations for Zio services received through EHR-integrated customers.
  • To learn more about how Zio can integrate with your Epic system, please visit Epic’s online showroom .

IRTC Lead Plaintiff Deadline Approaching; Contact Robbins LLP for Information About the Class Action Against iRhythm Technologies, Inc.

Retrieved on: 
Tuesday, February 27, 2024

For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • The Allegations: According to the complaint, during the class period, iRhythm represented to investors that the Zio AT monitor was a real-time monitor intended for a target audience of high-risk patients.
  • As a result of these representations, the price of iRhythm common stock traded at artificially inflated prices throughout the class period.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Pulsed Field Ablation Innovator Argá Medtech Announces €54 Million Oversubscribed Series B Capital Raise

Retrieved on: 
Tuesday, February 27, 2024

LAUSANNE, Switzerland and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Argá Medtech, a private company developing Coherent Sine-Burst Electroporation™ (CSE™), a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), today announced the closure of a €54M oversubscribed Series B funding. The round was led by the existing investors, Advent Life Sciences (UK) and Earlybird Health (Germany), as well as new investor Gilde Healthcare (the Netherlands) and an undisclosed strategic investor. The financing enables Argá Medtech to advance the development of its innovative CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU. With the funding, the company will also expand its US offices in San Diego, CA, in anticipation of its US clinical activities.  

Key Points: 
  • The financing enables Argá Medtech to advance the development of its innovative CSE™ Pulsed Field Ablation (PFA) system for treating AF through the execution of an IDE study in the US and a CE Mark study in the EU.
  • With the funding, the company will also expand its US offices in San Diego, CA, in anticipation of its US clinical activities.
  • “We are pleased to secure the support of such marquee investors who believe that Argá Medtech will revolutionize the atrial fibrillation ablation field,” said David Neale, CEO of Argá Medtech.
  • Argá Medtech’s CSE™ system uses a sinusoidal/sine wave, while other PFA platforms are typically powered by square wave energy sources.

IRHYTHM TECHNOLOGIES, INC. (NASDAQ: IRTC) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against iRhythm Technologies, Inc.

Retrieved on: 
Monday, February 26, 2024

If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.

Key Points: 
  • If you purchased or acquired iRhythm common stock, and/or would like to discuss your legal rights and options please visit iRhythm Technologies, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

Retrieved on: 
Thursday, February 22, 2024

Intermountain Medical Center is the leading provider of robotic heart rhythm care in Utah and the Intermountain Region.

Key Points: 
  • Intermountain Medical Center is the leading provider of robotic heart rhythm care in Utah and the Intermountain Region.
  • Electrophysiologists at the hospital have treated more than 1,000 patients using advanced robotic technology.
  • “Delivering outstanding patient care using the best technology and science is our primary focus at Intermountain,” said Michael Cutler, MD, cardiac electrophysiologist at Intermountain Medical Center.
  • “We look forward to continuing to support their successful and impactful robotic heart rhythm care program.”